| Literature DB >> 36248042 |
Himel Mondal1, Shaikat Mondal2.
Abstract
Entities:
Year: 2022 PMID: 36248042 PMCID: PMC9555376 DOI: 10.4103/ijem.ijem_500_21
Source DB: PubMed Journal: Indian J Endocrinol Metab ISSN: 2230-9500
Methods for observing accuracy of monitors for home glucose monitoring
| Method | Name | Criteria |
|---|---|---|
| Number-based | ISO 15197: 2003 | 95% of BGM reading must be within±15 mg/dL of reference reading if glucose level is <75 mg/dL and within 20% if glucose level is ≥75 mg/dL[ |
| ISO 15197: 2013; reviewed in 2018 | 95% of BGM reading must be within±15 mg/dL of reference reading if glucose level is <100 mg/dL and within±15% if glucose level is ≥100 mg/dL; 99% of the values should be within zones A and B in consensus error grid[ | |
| FDA (2003) | 95% of BGM reading must be within±15 mg/dL of reference reading if glucose level is <75 mg/dL and within 20% if glucose level is ≥75 mg/dL[ | |
| FDA (2016) | 95% of BGM reading must be within±15% of reference reading and 99% within±20%, regardless of glucose level[ | |
| ADA (1987) | 100% of BGM reading must be within±10% of the reference reading, regardless of glucose level[ | |
| ADA (1994) | 100% of BGM reading must be within±5% of the reference reading, regardless of glucose level[ | |
| CLIA (1988) | 80% of the BGM reading must be within±10% or±6 mg/dL of the reference reading, whichever is larger[ | |
| Graph-based | CEGA (1987) | Grids divide the upper and lower zone of A (<±20% of reference; or both SMBG and reference is<70 mg/dL; clinically appropriate decision), B (>± 20% of reference value; no impact on the clinical decision), C (overcorrection of acceptable blood glucose level), D (dangerous failure in detection or treatment), E (erroneous value - opposite to the reference value; leads to opposite treatment [treatment of hyperglycaemia when patients are actually hypoglycaemic and vice versa]) [Figure 3a][ |
| PEGA (2000) | Separate error grids for Type 1 and Type 2 DM. Grids divide upper and lower zone of A (clinically accurate; no effect on clinical action), B (altered clinical action; little or no effect on the outcome), C (altered clinical action; likely affect the outcome), D (altered clinical action; significant clinical risk), E (altered clinical action; dangerous consequences) [Figure 3b][ | |
| SEGA (2014) | Divided into risk levels of 0-0.5 (None), 0.5-1 (Mild, Lower), 1-1.5 (Mild, Higher), 1.5-2 (Moderate, Lower), 2-2.5 (Moderate, Higher), 2.5-3 (High, Lower), 3-3.5 (High, Upper), 3.5-4 (Extreme) [Figure 4b and 4c][ | |
| Other calculation | Modified Bland-Altman (1983) | Agreement between the reference and BGM reading by plotting reference blood glucose and difference (reference - meter) in glucose and separating accepted and non-accepted values with the help of gridlines according to defining criteria like ISO [Figure 2], FDA, ADA, and CLIA[ |
ADA: American Diabetes Association, BGM: Blood glucose monitor, CEGA: Clarke Error Grid Analysis, CLIA: Clinical Laboratory Improvement Amendments, FDA: Food and Drug Administration, ISO: International Organization for Standardization (https://www.iso.org/standard/54976.html), PEGA: Parkes Error Grid Analysis, SEGA: Surveillance Error Grid Analysis
Figure 1Example of a calculation of the accuracy of a blood glucose monitor according to ISO 15197:2013 criteria
Figure 2A modified Bland–Altman plot according to ISO 15197:2013 criteria. The area within the green dotted lines indicates accepted limits. The straight horizontal line from 0 to 100 on X-axis indicates the criteria “within ± 15 mg/dL of reference reading if glucose level is <100 mg/dL” and the tangent lines indicate the criteria “within ± 15% if glucose level is ≥100 mg/dL”
Figure 3Examples of error grid analysis graph – (a) Clarke Error Grid, (b) Parkes or Consensus Error Grid (for type 2 diabetes mellitus)
Figure 4(a) Brief steps for SEGA on the website (https://www.diabetestechnology.org/seg/), (b) SEG risk category-wise distribution of an example data, (c) an example SEGA graph